PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
12.48%
Revenue growth similar to ECL.AX's 12.80%. Walter Schloss would see if both companies share industry tailwinds.
18.99%
Gross profit growth 1.25-1.5x ECL.AX's 16.07%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
70.35%
EBIT growth above 1.5x ECL.AX's 30.84%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
70.35%
Operating income growth above 1.5x ECL.AX's 30.84%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
107.71%
Positive net income growth while ECL.AX is negative. John Neff might see a big relative performance advantage.
100.00%
Positive EPS growth while ECL.AX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
100.00%
Positive diluted EPS growth while ECL.AX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
82.12%
Share change of 82.12% while ECL.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
82.12%
Diluted share count expanding well above ECL.AX's 0.42%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-274.48%
Negative OCF growth while ECL.AX is at 23.54%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-14.34%
Negative FCF growth while ECL.AX is at 31.41%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-96.30%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-57.39%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-55.96%
Negative 3Y CAGR while ECL.AX stands at 36.03%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-103.53%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
83.39%
Positive OCF/share growth while ECL.AX is negative. John Neff might see a comparative advantage in operational cash viability.
-123.37%
Negative 3Y OCF/share CAGR while ECL.AX stands at 12.48%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
103.52%
Below 50% of ECL.AX's 238.67%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
126.47%
Below 50% of ECL.AX's 460.04%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-94.74%
Our R&D shrinks while ECL.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
580.87%
SG&A growth well above ECL.AX's 9.40%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.